See today's BioWorld MedTech
To read the full story, subscribe or sign in.

Qnovia launches Respirx inhaler trial

Oct. 15, 2024
By Annette Boyle
Qnovia Inc. received U.S. FDA clearance to start its clinical trial for Respirx, a nicotine inhaler designed as a replacement therapy for smoking.
BioWorld MedTech Regulatory Drug design, drug delivery and technologies Cancer Oncology Respiratory U.S.